AstraZeneca’s global biologics research and development arm MedImmune has entered into a licensing agreement with Allergan for the global rights to MEDI2070, which is currently in a Phase IIb clinical trial for moderate-to-severe Crohn’s disease and ready for Phase II for ulcerative colitis. Under the terms of the deal, Allergan will make an upfront payment to AstraZeneca of $250m for the exclusive, worldwide licence to develop and commercialise the drug.
{iframe}http://www.digitallook.com/news/news-and-announcements/astrazeneca-signs-drug-deal-with-allergan–1737780.html{/iframe}